• About us
• Contact

Advertisement

Organisation › Details

CinCor Pharma Inc.

CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, CIN-107, a first-in-class aldosterone synthase inhibitor, is in clinical development for the treatment of hypertension and primary aldosteronism. CinCor has raised $193 million to date in two private financings. *

 

	Start	2018-01-01 established
	Group	AstraZeneca (Group)
	Industry	baxdrosat (CIN-107)
	Industry 2	drug development
	Person	de Garidel, Marc (Abivax 202307 CEO before CinCor Pharma + Corvidia + Ipsen + Amgen + Eli Lilly)
	Street	5375 Medpace Way
	City	45227 Cincinnati, OH
	Tel	+1-844-531-1834
		Address record changed: 2021-10-20
Basic data	Employees	n. a.
		* Document for »About Section«: CinCor Pharma, Inc.. (10/12/21). "Press Release: CinCor Pharma Raises $143 Million in Series B Financing". Cincinnati, OH.
		Record changed: 2023-09-04

Advertisement

More documents for AstraZeneca (Group)

• [1] Amolyt Pharma SAS. (3/14/24). "Press Release: Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca. AstraZeneca Will Acquire Amolyt Pharma for up to $1.05 Billion in Total Consideration". Lyon & Cambridge, MA....
• [2] Allorion Therapeutics Inc.. (1/2/24). "Press Release: Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca". Natick, MA....
• [3] AstraZeneca plc. (12/26/23). "Press Release: AstraZeneca to Acquire Gracell, Furthering Cell Therapy Ambition across Oncology and Autoimmune Diseases"....
• [4] Gracell Biotechnologies Inc.. (12/26/23). "Press Release: Gracell Biotechnologies to Be Acquired by AstraZeneca, furthering Cell Therapy Ambition across Oncology and Autoimmune Diseases". San Diego, CA, Suzhou & Shanghai....
• [5] Icosavax, Inc.. (12/12/23). "Press Release: Icosavax, Inc. Announces Agreement to Be Acquired by AstraZeneca". Seattle, WA....
• [6] AstraZeneca plc. (12/12/23). "Press Release: AstraZeneca to Acquire Icosavax, Including Potential First-in-Class RSV and hMPV Combination Vaccine with Positive Phase II Data"....
• [7] AstraZeneca plc. (11/20/23). "Press Release: AstraZeneca Launches Evinova, a Health-tech Business to Accelerate Innovation across the Life Sciences Sector, the Delivery of Clinical Trials and Better Health Outcomes"....
• [8] AstraZeneca plc. (11/9/23). "Press Release: AstraZeneca Licenses Novel Agent for the Treatment of Cardiometabolic Conditions and Obesity [This press release is intended for investors and business / science media]"....
• [9] Nanoform Finland Oyj. (10/23/23). "Press Release: Nanoform Grant Global Starmap AI License to AstraZeneca". Helsinki....
• [10] AstraZeneca plc. (9/20/23). "Press Release: Alexion Completes Purchase and Licence Agreement for Early-stage Rare Disease Gene Therapy Portfolio from Pfizer"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.